Selected article for: "disease severity and key feature"
Author: Guervilly, Christophe; Burtey, Stephane; Sabatier, Florence; Cauchois, Raphaël; Lano, Guillaume; Abdili, Evelyne; Daviet, Florence; Arnaud, Laurent; Brunet, Philippe; Hraiech, Sami; Jourde-Chiche, Noémie; Koubi, Marie; Lacroix, Romaric; Pietri, Léa; Berda, Yaël; Robert, Thomas; Degioanni, Clara; Velier, Mélanie; Papazian, Laurent; Kaplanski, Gilles; Dignat-George, Françoise
Title: Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19
  • Cord-id: bm1qhjw5
  • Document date: 2020_8_19
    • ID: bm1qhjw5
    Snippet: Beside the commonly described pulmonary expression of the coronavirus disease 2019 (COVID-19), major vascular events have been reported. The objective of this study was to investigate whether increased levels of circulating endothelial cells (CEC) might be associated with severe forms of COVID-19. Ninety-nine patients with COVID-19 were enrolled in this retrospective study. Patients in the intensive care units (ICU) had significantly higher CEC counts than non-ICU patients and the extent of endo
    Document: Beside the commonly described pulmonary expression of the coronavirus disease 2019 (COVID-19), major vascular events have been reported. The objective of this study was to investigate whether increased levels of circulating endothelial cells (CEC) might be associated with severe forms of COVID-19. Ninety-nine patients with COVID-19 were enrolled in this retrospective study. Patients in the intensive care units (ICU) had significantly higher CEC counts than non-ICU patients and the extent of endothelial injury was correlated with putative markers of disease severity and inflammatory cytokines. Altogether, these data provide in vivo evidence that endothelial injury is a key feature of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • activation inflammation and longitudinal study: 1, 2
    • activation inflammation and lung express: 1
    • activation inflammation and lymphocyte platelet: 1, 2
    • activation inflammation and lymphocyte platelet count: 1
    • acute ards respiratory distress syndrome and longitudinal study: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and low mortality rate: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lymphocyte platelet: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and lymphocyte platelet count: 1, 2, 3
    • longitudinal study and low mortality: 1, 2, 3, 4, 5
    • longitudinal study and lymphocyte platelet: 1
    • low mortality and lymphocyte platelet: 1, 2, 3, 4, 5
    • low mortality and lymphocyte platelet count: 1, 2, 3